Edition:
United Kingdom

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

3.88USD
18 May 2018
Change (% chg)

$0.16 (+4.30%)
Prev Close
$3.72
Open
$3.78
Day's High
$3.89
Day's Low
$3.77
Volume
62,862
Avg. Vol
95,715
52-wk High
$7.24
52-wk Low
$2.86

Chart for

About

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address... (more)

Overall

Beta: 1.13
Market Cap(Mil.): $196.82
Shares Outstanding(Mil.): 46.09
Dividend: --
Yield (%): --

Financials

  CDXC.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -0.20 -- --
ROI: -39.31 1.57 14.38
ROE: -40.84 2.43 16.07

BRIEF-Chromadex Corp Appoints Rob Fried as Chief Executive Officer

* CHROMADEX APPOINTS FRANK JAKSCH AS EXECUTIVE CHAIRMAN, ROB FRIED AS CHIEF EXECUTIVE OFFICER AND KURT GUSTAFSON AS LEAD DIRECTOR

23 Apr 2018

BRIEF-Chromadex Corporation Q4 Loss Per Share $0.17

* Q4 REPORTED LOSS FROM CONTINUING OPERATIONS NEGATIVELY IMPACTED BY NON-CASH CHARGE OF $3.4 MILLION RELATED TO STOCK-BASED COMPENSATION

08 Mar 2018

BRIEF-Chromadex Chairman Stephen Allen Will Retire From The Board

* CHROMADEX CHAIRMAN STEPHEN ALLEN WILL RETIRE FROM BOARD OF DIRECTORS

16 Feb 2018

BRIEF-ChromaDex Corp Sees Q4 2017 Revenue About $7.5 Mln

* AN OPERATING LOSS FOR Q4 OF 2017 IS EXPECTED TO BE IN A RANGE OF $8.5 MILLION TO $9.5 MILLION

12 Feb 2018

BRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Health's Request To Invalidate U.S. Patent

* CHROMADEX - PATENT TRIAL AND APPEAL BOARD OF U.S. PATENT AND TRADEMARK OFFICE DENIED ELYSIUM HEALTH INC.'S REQUEST TO INVALIDATE U.S. PATENT

22 Jan 2018

BRIEF-ChromaDex And Watsons Expand Partnership With Tru Niagen Retail Launch In Singapore

* CHROMADEX AND WATSONS EXPAND PARTNERSHIP WITH TRU NIAGEN™ RETAIL LAUNCH IN SINGAPORE Source text for Eikon: Further company coverage:

08 Jan 2018

BRIEF-Chromadex Files For Resale Of Up To 5.6 Mln Shares Of Common Stock By The Selling Stockholders

* CHROMADEX CORP FILES FOR RESALE OF UP TO 5.6 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: [http://bit.ly/2kt48c4] Further company coverage:

14 Dec 2017

Earnings vs. Estimates